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Purpose: Primary thyroid mucosa-associated lymphoid tissue (MALT) lymphoma is a very rare subgroup of thyroid lym-
phoma, accounting for about 6 to 28% of all primary thyroid lymphomas. The purpose of this study was to evaluate its clin-
icopathological features and treatment outcomes. Methods: We identified seven patients with thyroid MALT lymphoma 
who were treated between January 1997 and December 2007, and reviewed their clinicopathological features and follow-up 
outcomes. Results: There were five female and two male patients, and their mean age was 73 years. All patients presented 
with palpable neck mass. Two patients had hoarseness and dyspnea. All patients had a history of Hashimoto’s thyroiditis 
with a mean of 175 months. Malignant lymphoma was suspected in only three patients using core needle biopsy. Four pa-
tients underwent thyroidectomy in the absence of preoperative pathologic confirmation, and histologic diagnosis was ob-
tained after surgery. As initial treatment, complete surgical resection was performed in five patients, radiotherapy in one, 
and a combination of chemotherapy and radiotherapy in one. Six patients were alive for the mean follow-up period of 66 
months and one patient died of unrelated causes. There were neither recurrences nor disease-specific mortalities. 
Conclusion: When primary thyroid MALT lymphoma occurs in the thyroid or is confined to the neck, it responds well to lo-
cal treatment such as surgical resection and external beam radiation therapy.
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INTRODUCTION
Primary thyroid lymphoma is a rare condition account-
ing for 1 to 5% of all thyroid malignancies and approx-
imately 2% of all malignant extranodal lymphomas [1]. 
Mucosa-associated lymphoid tissue (MALT) lymphoma is 
one of the rare variants, first described by Isaacson and 
Wright in 1984 [2]. Pure thyroid MALT lymphomas com-
prise about 6 to 28% of primary thyroid lymphomas, and 
are recognized as extranodal marginal zone B-cell lym-
phomas in the Revised European American Lymphoma 
classification of 1994 and the World Health Organization 
classification of 1999 [3-5]. Strictly, the thyroid gland is not 
a mucosal organ, being of foregut origin, and the lym-
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Table 1. Clinical characteristics of primary thyroid mucosa-associated lymphoid tissue lymphoma cases 
Patient Sex Age Diagnostic tool Stage Treatment modality Duration of Hashimoto’s Follow-up
1 F 85 Core biopsy IE RTx 240 mo Alive 37 mo
2 M 57 Core biopsy IE CTx, RTx   60 mo Alive 62 mo
3 M 62 FNAB, surgery IIE Surgery (TT with MRND) 120 mo Alive 143 mo
4 F 72 Surgery IIE Surgery (TT with MRND) 360 mo Expired (pancreatic cancer)
  25 mo
5 F 77 Core biopsy IE Surgery (HT) 144 mo Alive 38 mo
6 F 75 Surgery IE Surgery (TT) 120 mo Alive 10 mo
7 F 64 Surgery IE Surgery (TT) 180 mo Alive 148 mo
FNAB, fine needle aspiration biopsy; RTx, radiotherapy; CTx, chemotherapy; TT, total thyroidectomy; MRND, modified radical neck 
dissection; HT, hemithyroidectomy.
phoid tissue that accumulates in the thyroid in Hashimo-
to’s thyroiditis shares features with MALT. MALT lym-
phomas are thought to develop from lymphocytic tissue 
acquired during the course of a chronic inflammatory or 
autoimmune process. The thyroid is normally devoid of 
such lymphocytic tissue, and chronic autoimmune thyroi-
ditis (Hashimoto’s disease) has been associated with an in-
creased risk of lymphoma, including MALT lymphoma 
[6]. The coexistence of reactive and neoplastic processes in 
the thyroid gland may render the cytological and histo-
logical diagnosis of MALT lymphoma difficult. Clinically, 
most patients present in the seventh decade of life and 30 
to 50% of patients have compression symptoms, including 
dysphagia, dyspnea, stridor or hoarseness [7]. Primary 
thyroid MALT lymphomas are known to respond better to 
local treatments such as surgical resection and radio-
therapy, compared to diffuse large B-cell lymphomas. 
Also, primary thyroid MALT lymphomas tend to run an 
indolent clinical course with excellent prognosis, whereas 
exclusive diffuse large B-cell types or mixed types display 
a more aggressive clinical course [8]. The present study 
aimed to evaluate the clinicopathological features and 
treatment outcomes of patients with primary thyroid 
MALT lymphoma.
METHODS
We identified seven patients with a pathologic diag-
nosis of thyroid MALT lymphoma between January 1997 
and December 2007, and reviewed their clinicopatholo-
gical characteristics and treatment outcomes retrospec-
tively. The diagnosis of MALT lymphoma was given in 
cases with the presence of CD20 immunoreactivity in im-
munohistochemically stained specimens from fine needle 
aspiration biopsy (FNAB), core biopsy and surgery, and 
the histologic presence of small lymphoid cells with varia-
ble proportions of centrocyte-like cells, plasma cells, lym-
phoplasmacytoid lymphocytes, monocytoid B-cells, and 
interspersed large transformed lymphocytes. Mixed types 
with simultaneous presence of both MALT lymphoma 
and diffuse large B-cell lymphoma were excluded. We also 
investigated the patients’ stage (according to the Ann 
Arbor staging system) by examining the results from 
physical examination, blood counts, chemistry, chest 
X-rays, chest computed tomography (CT) scan, abdomi-
nal-pelvic CT, and bone marrow examination. This study 
was approved by our institutional review board. We 
adopted Musshoff’s modification of the Ann Arbor stag-
ing system, and primary thyroid lymphomas were staged 
as follows: IE: primary thyroid lymphoma with or without 
extension into the perithyroidal soft tissue; IIE: primary 
thyroid lymphomas with involvement of lymph nodes on 
the same side of the diaphragm; IIIE: primary thyroid lym-
phomas with involvement of lymph nodes on both sides of 
the diaphragm and/or spleen; and IVE: primary thyroid 
lymphomas with dissemination to other extranodal sites 
[9]. Although this study was not primarily focused on 
staging, some authors insist that primary thyroid lympho-
ma is defined as a lymphoma that only involves the thy-
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Fig. 1. (A) Gross appea-
rance of patient, (B) com-
puted tomography scan 
showing homogenously
enlarged thyroid gland. 
(C) Specimen showing 
firm, enlarged thyroid 
gland, and (D) microsco-
pic features of mucosa- 
associated lymphoid tis-
sue lymphoma (H&E, ×
100).
roid gland or the thyroid gland with its adjacent lymph 
nodes [10], restricting its stage to either stage IE or IIE un-
der the Ann Arbor staging system. The mean follow-up 
period was 66 months (range, 10 to 148 months).
RESULTS
The patients’ characteristics are listed in Table 1. There 
were five female and two male patients. At the time of di-
agnosis, the mean age of the patients was 73 years (range, 
57 to 85 years). All patients complained of palpable neck 
masses, and two patients also had hoarseness and dysp-
nea. All patients had a history of autoimmune Hashimo-
to’s thyroiditis, with a mean duration of 175 months 
(range, 60 to 360 months). One patient underwent FNAB, 
though the results were reported to be non-diagnostic. 
Core biopsy was performed in three cases for pathologic 
confirmation. Four cases, including the FNAB case, di-
rectly proceeded with curative surgery in the absence of 
preoperative pathologic confirmation because they dis-
played signs of acute enlargement as well as dysphagia 
and dyspnea during outpatient department follow-up, 
along with character changes in ultrasonography. Diagno-
sis was confirmed after surgery. The preoperative goitrous 
condition, postoperative gross specimen and microscopic 
feature (patient No.6) are shown in Fig. 1. As initial treat-
ment, complete surgical resection was performed in five 
cases, radiotherapy alone in one case, and a combination 
of chemotherapy and radiotherapy was given in one case. 
Among the patients that underwent surgery, there were 
two cases of total thyroidectomy, two cases of total thyroi-
dectomy with modified radical neck dissection, and one 
case of hemithyroidectomy. The radiotherapy-only case 
was performed using a dose of 4,500 cGy to the neck area. 
In the case of the patient that underwent combined chemo-
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therapy and radiotherapy, CHOP (cyclophosphamide, 
doxorubicin, vincristine, prednisolone) regimen was per-
formed and the radiation dose was 4,500 cGy at the lesion. 
Using the Ann Arbor staging system, five patients were 
stage IE and two patients were stage IIE. All of the patients 
achieved complete remission. One patient expired due to 
an unrelated cause (pancreatic cancer), and there were no 
disease-specific mortalities.
DISCUSSION
MALT lymphomas are very rare, but account for 85% of 
extranodal non-Hodgkin‘s lymphomas [2]. Although the 
stomach is by far the most common site of MALT lympho-
mas, they have also been described in various non-gastro-
intestinal sites, such as the salivary gland, thyroid, skin, 
conjunctiva, orbit, lung, breast, kidney, liver and even in 
the intracranial dura [11-18]. 
Two types of MALT can be identified in disparate or-
gans that do not correspond to peripheral sites of the im-
mune system. The native type consists of lymphoid tissue 
physiologically present in the gut (e.g., Peyer’s patches), 
whereas acquired MALT develops in sites of inflam-
mation in response to either infectious conditions such as 
Helicobacter pylori gastritis, or autoimmune processes such 
as Hashimoto’s thyroiditis [19,20]. In addition to being a 
causal factor of primary thyroid MALT lymphoma, it has 
been hypothesized that Hashimoto’s thyroiditis may fur-
ther develop into aggressive lymphomas [6,21]. This is the 
basis for treatment of primary thyroid MALT lymphomas, 
even though they have a better response to local treatment 
and a more favorable prognosis compared to diffuse large 
cell lymphomas. 
Normally, FNAB is a widely accepted technique for the 
diagnosis of thyroid nodules. However, primary thyroid 
lymphomas can be difficult to diagnose with FNAB alone. 
While the diagnostic accuracy of FNAB is quite low for dif-
fuse large B-cell lymphomas, it is even lower in the case of 
thyroid MALT lymphomas because the differentiation of 
MALT lymphomas from Hashimoto’s thyroiditis can be 
difficult by cytomorphology alone [22]. Core needle biop-
sy, though not considered a first-line method for the diag-
nosis of lymphomas, has been reported to have a higher 
diagnostic yield, with a sensitivity of 94.3%, a specificity of 
100%, and an accuracy of 95.2% [23]. As a method for diag-
nostic confirmation, core needle biopsy would be an alter-
native with a high priority along with FNAB. In our study, 
surgery was performed on a total of four cases prior to 
pathological confirmation, with a single case of FNAB and 
three cases of core needle biopsy. Clinically, when a patient 
with a past history of Hashimoto’s thyroiditis displays 
signs of abrupt thyroid enlargement or compression 
symptoms, the possibility of thyroid MALT lymphoma 
should be considered. This is especially true for the pa-
tients with a history over 5 years. 
The optimal treatment modality for primary thyroid 
MALT lymphoma remains yet to be defined. The benefits 
of surgical treatment in diffuse large B-cell lymphoma still 
remain in debate. While the combination of radiotherapy 
and chemotherapy is currently known as the standard 
treatment modality, local treatments such as total thyroi-
dectomy, or sole radiotherapy have been reported to be ef-
fective as well in MALT lymphoma limited to the thyroid 
[3,24]. There are some authors who advocate that the treat-
ment of neck lymph nodes with signs of metastasis from 
primary thyroid lymphoma should include adjuvant ra-
diotherapy in addition to surgery such as functional neck 
dissection [8]. The five cases of MALT lymphoma in this 
study that were localized to the thyroid did not show re-
currence or disease-related mortality regardless of treat-
ment modality. Also, the two cases (stage IIE) that under-
went modified radical neck dissection due to metastatic 
neck lymph nodes showed good outcome without addi-
tional adjuvant treatment. All of the patients remained re-
currence free after 10 years. Considering the excellent 
prognosis achieved in the two cases with lateral neck node 
metastasis by complete surgical resection without ad-
juvant treatment, it can be said that complete surgical re-
moval has significant value in treating primary thyroid 
MALT lymphomas even with regional lymph node 
metastasis. There are other similar reports where MALT 
lymphoma showed an indolent nature with an overall sur-
vival rate of more than 90% after only local control, where-
as cases of diffuse large B-cell lymphoma had and overall 
survival rate of 30 to 50% even with both surgery and ra-
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diotherapy performed [7,25,26]. Considering the results of 
the current study and previous reports, the most im-
portant modality for the treatment of localized primary 
thyroid MALT lymphoma will be complete loco-regional 
control of disease including surgical removal and radia-
tion therapy. Currently, there are no set protocols concern-
ing follow-up evaluations after the treatment of primary 
thyroid MALT lymphoma. There are cases where fluo-
rine-18 fluorodeoxyglucose-positron emission tomog-
raphy scans were used in the evaluation of recurrences, 
but its utility is yet to be determined [27].
In conclusion, when primary thyroid MALT lymphoma 
is suspected, core needle biopsy along with FNAB should 
be considered as a first-line histologic diagnostic tool. As 
initial treatment, local treatment, such as complete surgi-
cal resection and radiotherapy, should be performed when 
the disease is localized in the thyroid or when the meta-
stasis is limited to the regional lymph nodes. The role of 
adjuvant radiotherapy and chemotherapy is still undeter-
mined and is in need of further research.
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